C3 treats first European patient with CellSpray
Friday, 28 October, 2005
Tissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has treated a first European patient with its burns therapy CellSpray at Halle, in Germany.
CellSpray is intended for use in patients with between 30 per cent and 90 per cent of injuries to the body surface. It was launched in Europe in September, at the European Burns Association meeting in Portugal. Surgeons and medical practitioners in 20 hospitals in German speaking countries have been trained in using the CellSpray technology.
In July, the first patient was treated with C3's CellSpray XP, which is intended for use in patients with injuries of 10 to 30 per cent of the body.
CellSpray is available for sale in Austria, Denmark, Germany, The Netherlands and the UK, while CellSpray XP is also available for sale in Switzerland and Italy.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
